Skip to content
Etidocaine
Duranest (etidocaine) is a small molecule pharmaceutical. Etidocaine was first approved as Duranest on 1982-01-01. It is used to treat postoperative pain in the USA. It is known to target sodium channel protein type 2 subunit alpha.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Epinephrine
+
Etidocaine hydrochloride
Tradename
Company
Number
Date
Products
DURANESTAstraZenecaN-017751 DISCN1982-01-01
1 products, RLD
Hide discontinued
Epinephrine bitartrate
+
Etidocaine hydrochloride
Tradename
Company
Number
Date
Products
DURANESTAstraZenecaN-017751 DISCN1982-01-01
2 products, RLD
DURANESTDentsply PharmaceuticalN-021384 DISCN1982-01-01
1 products, RLD
Hide discontinued
Etidocaine hydrochloride
Tradename
Company
Number
Date
Products
DURANESTAstraZenecaN-017751 DISCN1982-01-01
2 products, RLD
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
postoperative pain—D010149G89.18
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
N: Nervous system drugs
— N01: Anesthetics
— N01B: Local anesthetics
— N01BB: Amide local anesthetics
— N01BB07: Etidocaine
— N01BB57: Etidocaine, combinations
HCPCS
No data
Clinical
Clinical Trials
1 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Therapeutic equivalencyD0138101————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameETIDOCAINE
INNetidocaine
Description
Etidocaine is an amino acid amide in which 2-[ethyl(propyl)amino]butanoic acid and 2,6-dimethylaniline have combined to form the amide bond. Used as a local anaesthetic (amide caine), it has rapid onset and long action properties, similar to bupivacaine, and is given by injection during surgical procedures and during labour and delivery. It has a role as a local anaesthetic.
Classification
Small molecule
Drug classlocal anesthetics
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CCCN(CC)C(CC)C(=O)Nc1c(C)cccc1C
Identifiers
PDB—
CAS-ID36637-18-0
RxCUI4171
ChEMBL IDCHEMBL492
ChEBI ID4904
PubChem CID37497
DrugBankDB08987
UNII IDI6CQM0F31V (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
SCN2A
SCN2A
Organism
Homo sapiens
Gene name
SCN2A
Gene synonyms
NAC2, SCN2A1, SCN2A2
NCBI Gene ID
6326
Protein name
sodium channel protein type 2 subunit alpha
Protein synonyms
HBSC II, Sodium channel protein brain II subunit alpha, Sodium channel protein type II subunit alpha, sodium channel protein, brain type 2 alpha subunit, sodium channel, voltage-gated, type II, alpha 1 polypeptide, sodium channel, voltage-gated, type II, alpha 2 polypeptide, sodium channel, voltage-gated, type II, alpha subunit, voltage-gated sodium channel subtype II, Voltage-gated sodium channel subunit alpha Nav1.2, voltage-gated sodium channel type II alpha subunit
Uniprot ID
Q9BZD0
Mouse ortholog
—
—
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 382 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
106 adverse events reported
View more details